Fisher Asset Management LLC Has $1.47 Billion Position in Novo Nordisk A/S (NYSE:NVO)

Fisher Asset Management LLC lowered its holdings in Novo Nordisk A/S (NYSE:NVO) by 3.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 14,193,693 shares of the company’s stock after selling 554,390 shares during the period. Fisher Asset Management LLC’s holdings in Novo Nordisk A/S were worth $1,468,338,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of NVO. Jennison Associates LLC boosted its stake in Novo Nordisk A/S by 100.3% in the third quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock worth $2,129,761,000 after purchasing an additional 11,727,507 shares in the last quarter. Polen Capital Management LLC acquired a new position in shares of Novo Nordisk A/S during the third quarter valued at $718,995,000. FMR LLC lifted its stake in shares of Novo Nordisk A/S by 122.7% during the third quarter. FMR LLC now owns 12,077,501 shares of the company’s stock valued at $1,098,328,000 after acquiring an additional 6,654,614 shares during the period. Morgan Stanley lifted its stake in shares of Novo Nordisk A/S by 96.5% during the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock valued at $838,021,000 after acquiring an additional 4,526,199 shares during the period. Finally, Loomis Sayles & Co. L P lifted its stake in shares of Novo Nordisk A/S by 91.7% during the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock valued at $827,354,000 after acquiring an additional 4,350,862 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the topic of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. BMO Capital Markets began coverage on Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target for the company. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target for the company. Finally, UBS Group began coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Stock Down 3.1 %

NVO stock traded down $3.97 during mid-day trading on Thursday, reaching $125.24. The company had a trading volume of 4,725,325 shares, compared to its average volume of 4,803,304. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The stock has a 50 day simple moving average of $127.22 and a two-hundred day simple moving average of $112.70. The company has a market capitalization of $562.02 billion, a price-to-earnings ratio of 46.34, a PEG ratio of 2.14 and a beta of 0.43. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The company had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. As a group, equities analysts predict that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.